NCT00933335View on ClinicalTrials.gov

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

December 31, 2009

Study Completion Date

August 31, 2010

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL

Tositumomab and Iodine I 131 Tositumomab

Tositumomab and Iodine I 131 Tositumomab

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY